Henry Schein, Inc. (NASDAQ:HSIC) CEO Sells $287,161.40 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) CEO Bradford C. Connett sold 4,036 shares of the business’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the sale, the chief executive officer now directly owns 62,688 shares of the company’s stock, valued at $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Henry Schein Stock Down 1.5 %

HSIC opened at $69.39 on Friday. The company has a market cap of $8.62 billion, a PE ratio of 28.56, a P/E/G ratio of 2.13 and a beta of 0.90. The business has a 50 day moving average price of $74.82 and a two-hundred day moving average price of $72.61. Henry Schein, Inc. has a 52 week low of $63.67 and a 52 week high of $82.49. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). The business had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.25 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the company posted $0.66 earnings per share. As a group, research analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HSIC. Jefferies Financial Group boosted their target price on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Wells Fargo & Company began coverage on Henry Schein in a report on Friday, February 14th. They issued an “equal weight” rating and a $80.00 target price for the company. Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and boosted their target price for the company from $69.00 to $84.00 in a report on Monday, January 6th. Mizuho began coverage on Henry Schein in a report on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 target price for the company. Finally, UBS Group reduced their target price on Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a report on Wednesday, February 26th. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $81.10.

Hedge Funds Weigh In On Henry Schein

A number of large investors have recently modified their holdings of HSIC. Palestra Capital Management LLC purchased a new position in shares of Henry Schein during the 4th quarter worth approximately $182,988,000. Lyrical Asset Management LP acquired a new stake in shares of Henry Schein in the 4th quarter worth approximately $126,655,000. Norges Bank acquired a new stake in shares of Henry Schein in the 4th quarter worth approximately $103,301,000. Steadfast Capital Management LP grew its holdings in shares of Henry Schein by 254.2% in the 4th quarter. Steadfast Capital Management LP now owns 1,637,808 shares of the company’s stock worth $113,336,000 after acquiring an additional 1,175,408 shares during the period. Finally, Holocene Advisors LP acquired a new stake in shares of Henry Schein in the 3rd quarter worth approximately $58,319,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.